Company Overview of Gilead Pharmasset LLC
Gilead Pharmasset LLC, a clinical-stage pharmaceutical company, engages in discovering, developing, and commercializing novel drugs to treat viral infections. The company primarily focuses on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection. Nucleoside/tide analogs are a class of compounds, which act as alternative substrates for the viral polymerase, inhibiting viral replication. The company has three clinical stage product candidates, including PSI-7977, an uracil nucleotide analog polymerase inhibitor, which is initiating a Phase III clinical trials; PSI-938, a guanine nucleotide analog polymerase inhibitor that...
303-A College Road East
Princeton, NJ 08540
Founded in 2004
Key Executives for Gilead Pharmasset LLC
Chief Financial Officer and Director
Chief Scientific Officer and Executive Vice President of Pharmaceutical Research
Senior Vice President of Business Development & Scientific Affairs
Vice President of Accounting and Administration
Compensation as of Fiscal Year 2016.
Gilead Pharmasset LLC Key Developments
Cipla to Launch Generic of Gilead Pharma's Hepatitis C Drug Sovald
Feb 13 15
Cipla has started work on launching generic versions of Gilead pharma's Hepatitis C drug Sovald. Hepcvir is the brand name under which Cipla will be selling the drug in India. The price is yet to be decided. Cipla is one of the several Indian companies which have signed a voluntary licence agreement with Gilead to sell generic versions in the Indian market. The decision comes even as Gilead is yet to receive a patent for the drug in India. It is also locked in dispute with the patent office over protection for an ancillary molecule. Sovaldi (chemical name Sofosbuvir) is considered to be one of the most effective drugs for treating Hep C. The drug created a huge controversy when Gilead announced that it will be pricing the drug at $84,000 in the United States. However, in India and other developing countries, the drug is priced at $900 for 12 weeks treatment.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries